Accessibility Menu
Tvardi Therapeutics logo

Tvardi Therapeutics(NASDAQ) TVRD

Current Price$2.51
Market Cap$23.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)-86%
5 Year-99%
1 Year-91%
1 Month+7%
Tvardi Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 2.512026-07-24
Tvardi Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-21.56%USD 3.202026-07-17
1 month+6.81%USD 2.352026-06-24
3 month-19.03%USD 3.102026-04-24
Year to date-41.63%USD 4.302025-12-31
1 year-90.8%USD 27.292025-07-24
3 year-97.5%USD 100.442023-07-25
5 year-99.42%USD 429.842021-07-23
Since inception-86.25%USD 18.252025-04-16

Tvardi Therapeutics Financials at a Glance

Market Cap

$23.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$15.44M

EPS (TTM)

-$3.09

P/E Ratio

-0.81

Dividend

$0.00

Beta (Volatility)

0.51 (Low)

Price

$2.51

Volume

8,134

Open

$2.57

Previous Close

$2.51

Daily Range

$2.48 - $2.61

52-Week Range

$1.50 - $43.65

Estimated Earnings Date

Aug 13, 2026

TVRD News

Foolcom-Featured.png

Tvardi Posts Q2 Net Income Turnaround

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tvardi Therapeutics

Tvardis develops oral medicines for people with serious lung and liver diseases. Its main drugs aim to slow disease progression and improve daily life. These treatments target patients with conditions that currently have limited options.

What’s in the Medicine Cabinet?

  • TTI-101 (Lead Drug): Oral therapy for lung and liver diseases; in Phase 2 trials; 0% of revenue.
  • TTI-109 (Pipeline Drug): Oral prodrug for improved delivery; in Phase 1 trials; 0% of revenue.
  • STAT3 Inhibitor Platform: Targets a protein linked to inflammation and tissue scarring; 0% of revenue.
  • Research and Development: Focused on new uses for STAT3 inhibitors; 0% of revenue.

Growth and Expansion: The Road So Far

  • Completed merger with Cara Therapeutics in April 2025, gaining $23.9M in net assets.
  • Launched Phase 1 trial for TTI-109 in June 2025 after FDA approval.
  • Started Phase 1b/2 trial for TTI-101 in liver cancer in 2025.
  • Expanded patent portfolio through in-licensing from Baylor College of Medicine.

What Makes Tvardi Stand Out?

Tvardis targets a protein, STAT3, that is difficult to block with drugs. Its medicines are taken by mouth, not injected, which may be easier for patients. The company holds patents for its drug methods and formulations.

Five Things You Need to Know

  • Revenue was $0 in QQ3 2025, down 100% from QQ3 2024.
  • Net loss was $6M in QQ3 2025, improved 55.7% from QQ3 2024.
  • Cash flow from operations was -$4M in QQ3 2025, up 69.6% from QQ3 2024.
  • R&D expense was $18M in 2025, down 23.8% from 2024.

Bottom Line

Tvardis remains focused on early-stage drug development for hard-to-treat diseases. The company has improved its financial efficiency but faces ongoing funding and clinical risks.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

12

CEO

Imran Alibhai, PhD

Website

tvarditherapeutics.com

Headquarters

Sugar Land, TX 77478, US

TVRD Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-64.17%

Return on Capital

-126.49%

Return on Assets

-59.80%

Earnings Yield

-1.23%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$23.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

9.38M

Volume

8.13K

Avg. Volume

2.27M

Financials (TTM)

Gross Profit

-$47.00K

Operating Income

-$29.45M

EBITDA

-$15.34M

Operating Cash Flow

-$24.67M

Capital Expenditure

$0.00

Free Cash Flow

-$24.67M

Cash & ST Invst.

$24.98M

Total Debt

$174.00K

Tvardi Therapeutics Performance Analysis

Tvardi Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 41,867,00081.8%
20232023-12-31USD 20,968,000-49.9%
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Tvardi Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-100.0%
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Tvardi Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -57.35-8.6%
20232023-12-31USD -78.7937.4%
20242024-12-31USD -11.42-85.5%
20252025-12-31USD -3.26-71.5%
Tvardi Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-92.3%
Q32025-09-3041.0%
Q42025-12-31-32.2%
Q12026-03-316.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$23.55MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.96M

N/A

Employees

12

N/A

Net Income

-$6.80M

-38.7%

EBITDA

-$6.80M

-237.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$24.98M

+12.0%

Total Debt

$174.00K

-99.5%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$54.00K

-99.8%

Short Term Debt

$120.00K

+13.2%

Return on Assets

-59.80%

N/A

Return on Invested Capital

-2.02%

N/A

Free Cash Flow

-$5.86M

+23.8%

Operating Cash Flow

-$5.86M

+23.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LTRNLantern Pharma Inc.
$2.75-4.18%
CALCCalciMedica, Inc.
$0.76+6.15%
FGENFibroGen, Inc.
$9.07-1.63%
PDSBPDS Biotechnology Corporation
$0.68-2.73%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
TAT&T
$24.13+0.05%
FFord Motor Company
$14.37+0.02%

Questions About TVRD

What is the current price of Tvardi Therapeutics?

Tvardi Therapeutics is trading at $2.51 per share.

What is the 52-week range for Tvardi Therapeutics?

Over the past 52 weeks, Tvardi Therapeutics has traded between $1.50 and $43.65.

How much debt does Tvardi Therapeutics have?

As of the most recent reporting period, Tvardi Therapeutics reported total debt of $174.00K.

How much cash does Tvardi Therapeutics have on hand?

Tvardi Therapeutics reported $19.85M in cash and cash equivalents in its most recent financial results.

What is Tvardi Therapeutics’s dividend yield?

Tvardi Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services